Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ANI Pharmaceuticals, Inc. - Common Stock
(NQ:
ANIP
)
77.77
-0.33 (-0.42%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ANI Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
1 Safe-and-Steady Stock Worth Your Attention and 2 That Underwhelm
February 09, 2026
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Via
StockStory
3 Small-Cap Stocks That Fall Short
February 03, 2026
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside...
Via
StockStory
1 Cash-Producing Stock on Our Buy List and 2 We Brush Off
January 25, 2026
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Via
StockStory
Topics
Supply Chain
3 Value Stocks with Questionable Fundamentals
January 20, 2026
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued...
Via
StockStory
6 Analysts Have This To Say About ANI Pharmaceuticals
↗
September 24, 2025
Via
Benzinga
ANI Pharmaceuticals (ANIP) Stock Trades Down, Here Is Why
January 13, 2026
Shares of specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) fell 3.3% in the morning session after investors appeared to take profits as the company announced strong preliminary 2025...
Via
StockStory
Stocks making big moves yesterday: OneMain, Nextpower, ANI Pharmaceuticals, Akamai Technologies, and Lemonade
January 13, 2026
Check out the companies making headlines yesterday:
Via
StockStory
Why ANI Pharmaceuticals (ANIP) Stock Is Trading Up Today
January 12, 2026
Shares of specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) jumped 13.6% in the afternoon session after the company provided strong 2026 financial guidance that surpassed analyst...
Via
StockStory
Topics
Artificial Intelligence
Supply Chain
1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 That Underwhelm
January 07, 2026
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because...
Via
StockStory
3 Reasons to Avoid ANIP and 1 Stock to Buy Instead
January 04, 2026
Since January 2021, the S&P 500 has delivered a total return of 83.6%. But one standout stock has nearly doubled the market - over the past five years, ANI Pharmaceuticals has surged 147% to $77.55 per...
Via
StockStory
Topics
Stocks
Supply Chain
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away
↗
December 28, 2025
ANI is firing on all cylinders operationally, which makes this exit less about fundamentals and more about portfolio discipline at a moment when expectations might be sky-high.
Via
The Motley Fool
Topics
Regulatory Compliance
3 Healthcare Stocks We’re Skeptical Of
December 16, 2025
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 15.6% over...
Via
StockStory
Topics
Stocks
3 Small-Cap Stocks We’re Skeptical Of
December 10, 2025
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...
Via
StockStory
1 Russell 2000 Stock to Consider Right Now and 2 We Avoid
November 18, 2025
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher...
Via
StockStory
The 5 Most Interesting Analyst Questions From ANI Pharmaceuticals’s Q3 Earnings Call
November 14, 2025
ANI Pharmaceuticals delivered a third quarter marked by substantial year-over-year growth, with management attributing performance to strong momentum across its Rare Disease and Generics segments. CEO...
Via
StockStory
Topics
Earnings
Generic Pharmaceuticals Stocks Q3 Recap: Benchmarking ANI Pharmaceuticals (NASDAQ:ANIP)
November 11, 2025
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including ANI Pharmaceuticals (NASDAQ:ANIP) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Generic Pharmaceuticals Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) Simply the Best
November 11, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
The Bancorp: Building the Pulse of Digital Finance One Partnership at a Time
↗
November 10, 2025
The Bancorp: Building the Pulse of Digital Finance One Partnership at a Time
Via
The Motley Fool
ANIP Q3 Deep Dive: Rare Disease Momentum and Generics Expansion Drive Upgraded Outlook
November 08, 2025
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 53.6% year on year to $227.8 million. The...
Via
StockStory
ANI PHARMACEUTICALS INC (NASDAQ:ANIP) Reports Record Q3 2025 Earnings, Beating Estimates
↗
November 07, 2025
ANI Pharmaceuticals (ANIP) smashed Q3 2025 earnings estimates, posting record revenue and a 14% EPS beat. The company also raised its full-year 2025 guidance.
Via
Chartmill
ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Strong Q3 Numbers, Stock Soars
November 07, 2025
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 53.6% year on year to $227.8 million. The...
Via
StockStory
Examining the Future: ANI Pharmaceuticals's Earnings Outlook
↗
November 06, 2025
Via
Benzinga
ANI Pharmaceuticals (ANIP) To Report Earnings Tomorrow: Here Is What To Expect
November 05, 2025
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting results this Friday before the bell. Here’s what to look for.
Via
StockStory
Topics
Artificial Intelligence
Earnings Scheduled For November 7, 2025
↗
November 07, 2025
Via
Benzinga
3 Profitable Stocks We’re Skeptical Of
October 27, 2025
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...
Via
StockStory
ANI Pharmaceuticals Inc (NASDAQ:ANIP) Screens as High Growth Momentum Stock Meeting Minervini Trend Template
↗
October 20, 2025
ANI Pharmaceuticals (ANIP) combines strong technical uptrend with explosive earnings and sales growth, fitting a proven strategy for spotting potential market leaders.
Via
Chartmill
ANI Pharmaceuticals Inc (NASDAQ:ANIP) Combines Strong Growth Momentum with Bullish Technical Setup
↗
October 13, 2025
ANI Pharmaceuticals (ANIP) shows strong growth momentum with 76% EPS growth and a positive technical setup, signaling a potential breakout opportunity.
Via
Chartmill
ANI Pharmaceuticals (ANIP): Buy, Sell, or Hold Post Q2 Earnings?
October 07, 2025
ANI Pharmaceuticals has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 37.4% to $92.06 per share while the index has...
Via
StockStory
Topics
Stocks
Supply Chain
3 Low-Volatility Stocks We’re Skeptical Of
September 29, 2025
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.
Via
StockStory
3 Small-Cap Stocks We Approach with Caution
September 23, 2025
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.